Company research · Johnson & Johnson
Johnson & Johnson: Q1 2026 sales fell 2.0% to US$24.06 billion
The question
What is Johnson & Johnson: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?
The 12 searches GAR ran
- Johnson & Johnson news 2026
- Johnson & Johnson criticism controversy concerns
- Johnson & Johnson company what it does products services
- Johnson & Johnson company overview founded headquarters industry
- Johnson & Johnson annual revenue employees 2025
- Johnson & Johnson revenue profit results 2026
- Johnson & Johnson funding round raised investors valuation
- Johnson & Johnson owner parent company stock listing
- Johnson & Johnson CEO founder leadership team
- Johnson & Johnson chief executive executives board
- Johnson & Johnson press release announcement 2026
- Johnson & Johnson mission strategy statement
GAR’s answer
Johnson & Johnson, a global healthcare leader operating in Pharmaceuticals, MedTech, and Consumer Health, reported Q1 2026 sales of US$24.06 billion, a 2.0% decrease from Q4 2025.
What we found
What it does
Johnson & Johnson is a global leader in healthcare, dedicated to innovating solutions that improve the health and well-being of people worldwide. The company operates across three key segments: Pharmaceuticals, MedTech, and Consumer Health, offering a broad range of products and services. It distinguishes itself through a commitment to research and development, aiming to prevent, treat, and cure disease with increasingly sophisticated and personalized approaches. The company’s analytical context includes medicines, research in areas such as oncology, immunology, and biotechnology, and healthcare-technology collaborations. Its business serves healthcare professionals, health systems, and patients, where scientific evidence, trusted delivery, and long development cycles shape value creation. In 2026, the company reported that it had raised its quarterly cash dividend for 64 consecutive years. At that time, the company was able to sustain the revenue and earnings growth necessary to implement dividend increases and maintain the stock's valuation of around 21 times forward earnings. The company stated in 2026 that it was tackling the world’s toughest health challenges and delivering long-term value for its stakeholders. As of 2026, the company’s business segments included Innovative Medicine and MedTech. The Innovative Medicine segment covered Immunology, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, and Pulmonary Hypertension. The MedTech segment included Surgery, Orthopaedics, Interventional Solutions, and Vision. The company developed pharmaceuticals, medical equipment, and a range of consumer goods. It operated in healthcare development within the medical and pharmaceutical sectors, developing treatments and technologies for complex diseases and providing a range of healthcare solutions. [1] [2] [3] [4] [5] [6] [7]
The numbers
In 2025, Johnson & Johnson reported worldwide sales of US$94.19 billion, an increase from US$88.82 billion in 2024. The company’s net earnings for 2025 were US$26.80 billion, compared to US$14.07 billion in 2024. As of 2025, the company employed 130,000 people globally. Sales by segment in 2025 included US$60.40 billion for Innovative Medicine and US$33.79 billion for MedTech. Geographically, United States sales accounted for US$53.75 billion, while international sales totaled US$40.44 billion, with Europe contributing US$21.54 billion. Quarterly figures show reported sales of US$24.56 billion in the fourth quarter of 2025 and US$24.06 billion in the first quarter of 2026, representing a 2.0% decrease between those periods. In its annual SEC filing for the period ending December 28, 2025, the company reported revenue of 94193000000 USD and net income of 26804000000 USD. For the prior year ending December 29, 2024, the filing listed revenue of 88821000000 USD and net income of 14066000000 USD. Looking ahead to 2026, the company forecast operational sales of $99.5 billion to $100.5 billion and earnings of $11.43 to $11.63 per share. In the fourth quarter, adjusted profit reached $6 billion, or $2.46 per share. [8] [9] [10] [13]
| Metric (2025) | Value |
|---|---|
| worldwide sales in 2025 | US$94.19 billion [8] |
| net earnings in 2025 | US$26.80 billion [8] |
| global employees in 2025 | 130,000 [9] |
| Innovative Medicine sales in 2025 | US$60.40 billion [8] |
| MedTech sales in 2025 | US$33.79 billion [8] |
| United States sales in 2025 | US$53.75 billion [8] |
| international sales in 2025 | US$40.44 billion [8] |
| Europe sales in 2025 | US$21.54 billion [8] |
Funding and ownership
As of 2026, Johnson & Johnson had a market capitalization of $647.6B. The company's share price stood at $268.73. On October 16, 2026, the stock price increased by $2.43, representing a change of +0.91%. This movement was described as a rise of 0.9% on Tuesday. These figures were reported by stockdecider.com. [11]
What the company says
Johnson & Johnson states its mission is to blend heart, science, and ingenuity to profoundly impact health for humanity. In 2024, the company invested $17.2 billion in research and development. As of 2024, Johnson & Johnson employed 138,000 people worldwide. [12]
Where the sources disagree
No disagreement found among the figures GAR compares: the same measure for the same period, and stakes in the same company. Other figures on this page are not checked against each other.
Analysis
Johnson & Johnson's sales decreased by 2.0% when moving from the fourth quarter of 2025 to the first quarter of 2026, indicating a slight drop in revenue over that period. This means the company generated less income in the most recent quarter compared to the one immediately preceding it. [8]
Strengths and concerns
Strengths
- The company grew its worldwide sales from US$88.82 billion in 2024 to US$94.19 billion in 2025, indicating expanding market reach. [8]
- Net earnings increased significantly from US$14.07 billion in 2024 to US$26.80 billion in 2025, reflecting improved profitability. [8]
- Johnson & Johnson has raised its quarterly cash dividend for 64 consecutive years, demonstrating a long-term commitment to returning value to shareholders. [3]
- The company invested US$17.2 billion in research and development in 2024, supporting its ability to innovate and maintain a competitive edge in healthcare. [12]
Concerns
- Change in revenue from Q4 2025 to Q1 2026: -2.0%. [8]
- The company faces geographic concentration risk, with United States sales of US$53.75 billion in 2025 accounting for a majority of its worldwide sales of US$94.19 billion. [8]
- There is a segment concentration risk, as Innovative Medicine generated US$60.40 billion in sales in 2025, representing the largest portion of the company's total worldwide sales of US$94.19 billion. [8]
Sources
- Johnson & Johnson — Employer profile in United States | KarieR.co
- Johnson & Johnson: Drug Development, 6 Analyses 2026–2027 | Pestel-Analysis.com
- Johnson & Johnson: Changing health for humanity
- JOHNSON & JOHNSON Profile - Business Structure, Industry & Snapshot
- Strategy Study: How Johnson & Johnson Became A Household Name
- Johnson & Johnson - Products, Competitors, Financials, Employees, Headquarters Locations
- Johnson and Johnson Statistics and Facts
Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 28 October 2026; updated 28 October 2026. Suggest a correction · Read as markdown